<code id='96DEAAE973'></code><style id='96DEAAE973'></style>
    • <acronym id='96DEAAE973'></acronym>
      <center id='96DEAAE973'><center id='96DEAAE973'><tfoot id='96DEAAE973'></tfoot></center><abbr id='96DEAAE973'><dir id='96DEAAE973'><tfoot id='96DEAAE973'></tfoot><noframes id='96DEAAE973'>

    • <optgroup id='96DEAAE973'><strike id='96DEAAE973'><sup id='96DEAAE973'></sup></strike><code id='96DEAAE973'></code></optgroup>
        1. <b id='96DEAAE973'><label id='96DEAAE973'><select id='96DEAAE973'><dt id='96DEAAE973'><span id='96DEAAE973'></span></dt></select></label></b><u id='96DEAAE973'></u>
          <i id='96DEAAE973'><strike id='96DEAAE973'><tt id='96DEAAE973'><pre id='96DEAAE973'></pre></tt></strike></i>

          Home / Wikipedia / leisure time

          leisure time


          leisure time

          author:fashion    Page View:6
          translucent 3D DNA helix with blue and purple background
          Adobe

          Verve Therapeutics said Monday that it had received clearance from the Food and Drug Administration to conduct a clinical trial in the U.S. of its experimental, gene-editing treatment for a common form of heart disease.

          The FDA’s action removes a clinical hold on Verve’s CRISPR-based therapy, called VERVE-101, that was placed on it last November. Verve now intends to recruit participants from U.S. sites into a Phase 1 study that’s been underway since last year in New Zealand and the United Kingdom.

          advertisement

          “We’re thrilled to get this clearance for VERVE-101,” said Verve CEO Sek Kathiresan. “Our study is called HEART-1 and our plan now is to activate U.S. sites.”

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In